Moreover, modulators of the NLRP3-inflammasome activation pathway are investigated in pre-clinical studies and about to enter clinical trials in MDS as novel targeted treatments in lower-risk disease [22,23]. The gene discussed is NLRP3; the disease is myelodysplastic syndrome.